Eli Lilly has agreed to acquire AtaiBeckley, a psychedelics-focused biotech, extending its push into experimental mental-health treatments. Multiple outlets report the transaction is valued at an initial $2.8 billion, with total potential consideration rising to as much as $3.8 billion, depending on deal terms and future milestones. Reports say the acquisition would give Lilly access to AtaiBeckley’s neuroscience pipeline, including experimental therapies associated with psychedelics such as DMT and MDMA.
The news also drew a sharp market reaction for AtaiBeckley, with one outlet citing a roughly 50% rise in premarket trading after reports surfaced that Lilly was in advanced talks. Coverage characterizes the deal as part of a broader pattern of pharmaceutical-company acquisitions in the psychedelics space, as experimental treatments gain investor and commercial attention.
Financial terms, pipeline details, and potential milestone-driven payments are consistent across the reports, while emphasis differs by outlet—some focus on deal size and structure, others on market impact or the therapeutic approach.
